Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer
- PMID: 33201352
- PMCID: PMC8065006
- DOI: 10.1007/s10120-020-01141-w
Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer
Abstract
Background: Gastric microbiome, other than Helicobacter pylori, plays a role in the tumorigenesis of gastric cancer (GC). Patients who undergo endoscopic submucosal dissection for early GC have a high risk of developing metachronous GC even after successful eradication of H. pylori. Thus, we investigated the microbial profiles and associated changes in such patients after the eradication of H. pylori.
Methods: A total of 19 H. pylori-infected patients with early GC who were or to be treated by endoscopic resection, with paired biopsy samples at pre- and post-eradication therapy, were retrospectively enrolled. Ten H. pylori-negative patients were enrolled as controls. Biopsy samples were analyzed using 16S rRNA sequencing.
Results: H. pylori-positive patients exhibited low richness and evenness of bacteria with the deletion of several genera, including Blautia, Ralstonia, Faecalibacterium, Methylobacterium, and Megamonas. H. pylori eradication partially restored microbial diversity, as assessed during a median follow-up at 13 months after eradication therapy. However, post-eradication patients had less diversity than that in the controls and possessed a lower abundance of the five genera mentioned above. The eradication of H. pylori also altered the bacterial composition, but not to the same extent as that in controls. The microbial communities could be clustered into three separate groups: H. pylori-negative, pre-eradication, and post-eradication.
Conclusion: Changes in dysbiosis may persist long after the eradication of H. pylori in patients with a history of GC. Dysbiosis may be involved in the development of both primary and metachronous GC after the eradication of H. pylori in such patients.
Keywords: Dysbiosis; Eradication; Gastric cancer; Helicobacter pylori.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures





Comment in
-
Comment on: "Long‑term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer. Gastric Cancer, 2020 Nov 17" by Watanabe et al.Gastric Cancer. 2021 Jul;24(4):978-979. doi: 10.1007/s10120-020-01152-7. Epub 2021 Jan 7. Gastric Cancer. 2021. PMID: 33411059 No abstract available.
-
Reply to the letter by Ouyang et al. regarding our manuscript "Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer".Gastric Cancer. 2021 Jul;24(4):980-981. doi: 10.1007/s10120-021-01198-1. Epub 2021 May 19. Gastric Cancer. 2021. PMID: 34009534 No abstract available.
Similar articles
-
Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.Aliment Pharmacol Ther. 2017 Oct;46(8):758-767. doi: 10.1111/apt.14263. Epub 2017 Aug 11. Aliment Pharmacol Ther. 2017. PMID: 28799258
-
Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer.Gut. 2020 Sep;69(9):1598-1607. doi: 10.1136/gutjnl-2019-319696. Epub 2019 Dec 19. Gut. 2020. PMID: 31857433 Free PMC article.
-
Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis.Front Cell Infect Microbiol. 2022 May 4;12:899248. doi: 10.3389/fcimb.2022.899248. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35601105 Free PMC article.
-
Reply to the letter by Ouyang et al. regarding our manuscript "Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer".Gastric Cancer. 2021 Jul;24(4):980-981. doi: 10.1007/s10120-021-01198-1. Epub 2021 May 19. Gastric Cancer. 2021. PMID: 34009534 No abstract available.
-
Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis.J Clin Gastroenterol. 2020 Mar;54(3):235-241. doi: 10.1097/MCG.0000000000001195. J Clin Gastroenterol. 2020. PMID: 30829904
Cited by
-
Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets.Protein Cell. 2024 Apr 1;15(4):239-260. doi: 10.1093/procel/pwad052. Protein Cell. 2024. PMID: 37946397 Free PMC article. Review.
-
Gut microbiome and gastric cancer: microbial interactions and therapeutic potential.Gut Pathog. 2025 Jul 26;17(1):56. doi: 10.1186/s13099-025-00729-w. Gut Pathog. 2025. PMID: 40713842 Free PMC article. Review.
-
Gastric microbiota in gastric cancer: Different roles of Helicobacter pylori and other microbes.Front Cell Infect Microbiol. 2023 Jan 10;12:1105811. doi: 10.3389/fcimb.2022.1105811. eCollection 2022. Front Cell Infect Microbiol. 2023. PMID: 36704105 Free PMC article. Review.
-
The influence of Helicobacter pylori, proton pump inhibitor, and obesity on the gastric microbiome in relation to gastric cancer development.Comput Struct Biotechnol J. 2023 Nov 30;23:186-198. doi: 10.1016/j.csbj.2023.11.053. eCollection 2024 Dec. Comput Struct Biotechnol J. 2023. PMID: 38075398 Free PMC article. Review.
-
Interactions between H. pylori and the Gastric Microbiome: Impact on Gastric Homeostasis and Disease.Curr Opin Physiol. 2021 Jun;21:57-64. doi: 10.1016/j.cophys.2021.04.003. Epub 2021 Apr 24. Curr Opin Physiol. 2021. PMID: 34113748 Free PMC article.
References
-
- Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–397. doi: 10.1016/S0140-6736(08)61159-9. - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous